Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.58 |
| ▸ | PRKACB | P22694 | 1/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.52 |
| ▸ | CD47 | Q08722 | 1/20 | 0.52 |
| ▸ | GLP1R | P43220 | 7/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | GCGR | P47871 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 2/20 | 0.50 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517075 | 0.95 | C5AR1 (0.54) | C5AR1CD47MC4RIL23R | |
| SCHEMBL31140227 | 0.94 | C5AR1 (0.55) | C5AR1PRKACBNPBWR1CD47GLP1R | |
| SCHEMBL29540710 | 0.92 | C5AR1 (0.58) | C5AR1NPBWR1CD47GLP1RIL23R | |
| SCHEMBL30510367 | 0.92 | MC4R (0.52) | C5AR1MC4R | |
| SCHEMBL31140223 | 0.92 | TUBB4A (0.56) | C5AR1NPBWR1GLP1RCXCR4IL23R | |
| SCHEMBL29476484 | 0.91 | MC4R (0.50) | C5AR1MC4R | |
| SCHEMBL29476447 | 0.91 | MC4R (0.50) | C5AR1MC4R | |
| SCHEMBL30878115 | 0.90 | GHSR (0.57) | C5AR1 | |
| SCHEMBL29419495 | 0.90 | C5AR1 (0.59) | C5AR1NPBWR1GLP1RGCGRMC4R | |
| SCHEMBL29973131 | 0.89 | C5AR1 (0.55) | C5AR1CD47GLP1RGCGRIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119119190-A | Melanocortin receptor ligands | 益普生制药股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-105837661-B | Melanocortin receptor ligands | 益普生制药股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-116507353-A | Methods of treating melanocortin-4 receptor pathway-related disorders | 节奏制药公司 | 2023-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | C5AR1 1092/4885PRKACB 1262/4885NPBWR1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.